Perspectives for personalized therapy for patients with multidrug-resistant tuberculosisShow others and affiliations
2018 (English)In: Journal of Internal Medicine, ISSN 0954-6820, E-ISSN 1365-2796, Vol. 284, no 2, p. 163-188Article, review/survey (Refereed) Published
Abstract [en]
According to the World Health Organization (WHO), tuberculosis is the leading cause of death attributed to a single microbial pathogen worldwide. In addition to the large number of patients affected by tuberculosis, the emergence of Mycobacterium tuberculosis drug-resistance is complicating tuberculosis control in many high-burden countries. During the past 5years, the global number of patients identified with multidrug-resistant tuberculosis (MDR-TB), defined as bacillary resistance at least against rifampicin and isoniazid, the two most active drugs in a treatment regimen, has increased by more than 20% annually. Today we experience a historical peak in the number of patients affected by MDR-TB. The management of MDR-TB is characterized by delayed diagnosis, uncertainty of the extent of bacillary drug-resistance, imprecise standardized drug regimens and dosages, very long duration of therapy and high frequency of adverse events which all translate into a poor prognosis for many of the affected patients. Major scientific and technological advances in recent years provide new perspectives through treatment regimens tailor-made to individual needs. Where available, such personalized treatment has major implications on the treatment outcomes of patients with MDR-TB. The challenge now is to bring these adances to those patients that need them most.
Place, publisher, year, edition, pages
WILEY , 2018. Vol. 284, no 2, p. 163-188
Keywords [en]
individualized medicine; MDR-TB; personalized medicine; XDR-TB
National Category
General Practice
Identifiers
URN: urn:nbn:se:liu:diva-150237DOI: 10.1111/joim.12780ISI: 000439800900005PubMedID: 29806961OAI: oai:DiVA.org:liu-150237DiVA, id: diva2:1240713
Note
Funding Agencies|German Center for Infection Research (DZIF); Swedish Research council; Swedish Heart and Lung Foundation (Oscar II Jubilee Foundation); South African National Research Foundation; Leibniz Research Campus EvoLung
2018-08-222018-08-222018-08-22